Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection
Open Access
- 13 March 2013
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (12), 1812-1819
- https://doi.org/10.1093/cid/cit145
Abstract
Background. Hepatitis B virus (HBV) infection is common in individuals infected with human immunodeficiency virus, especially in men who have sex with men (MSM). Almost all currently used regimens of antiretroviral therapy (ART) contain lamivudine (LAM) or tenofovir disoproxil fumarate (TDF), both of which have significant anti-HBV activity. However, the prophylactic effect of ART on HBV infection has not been assessed previously. Methods. Non-HBV-vaccinated HIV-infected MSM were serologically evaluated for HBV infection using stocked serum samples. Cases negative for HBV surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HBV core antigen (anti-HBc) in first serum samples were serologically followed until last available stocked samples. HBV genotype and LAM-resistant mutation (rtM204V/I) were analyzed in cases that became HBsAg-positive. Results. The first stocked samples were negative for all analyzed HBV serological markers in 354 of 1434 evaluated patients. The analysis of their last samples indicated HBV incident infection in 43 of them during the follow-up period. The rate of incident infections was lower during LAM- or TDF-containing ART (0.669 incident infections in 100 person-years) than during no ART period (6.726 incident infections in 100 person-years) and other ART (5.263 incident infections in 100 person-years) (P < .001). Genotype A was most prevalent (76.5%), and LAM-resistant HBV was more frequent in incident infections during LAM-containing ART (50.0%) than in those during no ART and other ART (7.1%) (P = .029). Conclusions. LAM- and TDF-containing ART regimens seem to provide prophylaxis against HBV infection, although drug-resistant strains seem to evade these effects.Keywords
This publication has 40 references indexed in Scilit:
- HIV–HBV Coinfection — A Global ChallengeNew England Journal of Medicine, 2012
- Outbreak of Infections by Hepatitis B Virus Genotype A and Transmission of Genetic Drug Resistance in Patients Coinfected with HIV-1 in JapanJournal of Clinical Microbiology, 2011
- Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in JapanAntiviral Research, 2010
- Viral hepatitis and HIV co-infectionAntiviral Research, 2010
- HIV/hepatitis B virus co-infection: current challenges and new strategiesJournal of Antimicrobial Chemotherapy, 2009
- Viral Hepatitis in HIV InfectionNew England Journal of Medicine, 2007
- Management of patients co-infected with hepatitis B virus and HIVThe Lancet Infectious Diseases, 2005
- Prevalence of Chronic Hepatitis B and Incidence of Acute Hepatitis B Infection in Human Immunodeficiency Virus–Infected SubjectsThe Journal of Infectious Diseases, 2003
- HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapyHIV Medicine, 2003
- Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual menHepatology, 1999